Having trouble accessing articles? Reset your cache.

Bayer-backed Pyxis debuts with $22M to pursue new immuno-oncology targets

Pyxis’ tumor microenvironment-based technology to identify immuno-oncology targets developed by cancer researcher Thomas Gajewski prompted Leap by Bayer to lead the start-up’s $22 million series A round.

Agent Capital, Ipsen Group (Euronext:IPN; Pink:IPSEY), Longwood and angel

Read the full 365 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE